Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Stopped early · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine may help ixabepilone work better by making tumor cells more sensitive to the drug. PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone given together with hydroxychloroquine and to see how well they work in treating patients with metastatic breast cancer.
Key facts
- Study ID
- NCT00765765
- Run by
- University of Medicine and Dentistry of New Jersey
- People needed
- 6
- Starts
- 2009-02-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2023-08-09
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Institute of New Jersey at Hamilton — Hamilton, New Jersey, United States
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.